Reistone Starts Global Trial of JAK1 Inhibitor for Atopic Dermatitis
May 14, 2021 at 03:50 AM EDT
Shanghai Reistone Biopharma has started a global Phase III clinical trial of its Janus kinase type 1 (JAK1) inhibitor in patients with Atopic Dermatitis. SHR0302 is a novel, oral JAK1 inhibitor that Reistone expects will offer an improved safety and efficacy profile compared to pan-JAK inhibitors by avoiding the hematological side effects of JAK2 inhibition. The company, which focuses on bringing China-sourced novel products for autoimmune/inflammatory conditions to global markets, in-licensed global rights to the candidate in autoimmune diseases from Jiangsu Hengrui Medicine. More details.... Share this with colleagues: // //
